Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by ... ( FORT LEE N.J. Oct. 25 /- Neurologix I...)

HOME >> MEDICINE >> TECHNOLOGY

Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix

Date:10/25/2010

FORT LEE, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX) today announced that a landmark paper, published on October 20th in Science Translational Medicine demonstrating the importance of the p11 gene in modulating depression in mice, utilized a gene therapy approach to reverse depression in mice for which the Company holds exclusive development rights. Based on the findings reported in the paper, gene therapy may have potential as a new treatment option for people who suffer from severe depression.In the study, reduced levels of the p11 protein in the nucleus accumbens (NAcc) of the brain were associated with depressive behaviors in mice. An AAV vector (adeno-associated virus, a disabled, non-pathogenic virus) was used to deliver the p11 gene back into the NAcc of mice who were lacking the p11 protein, reversing the depressive behavior and returning the animals to normal function.

The study also examined samples of brain tissue from a group of deceased human patients, half of whom had severe depression. It was found that there were significantly reduced levels of p11 in the NAcc of depressed patients compared to those without depression. This further highlights the importance of this research in providing a new avenue for future treatment of this widespread disorder.

Neurologix holds the exclusive license to a patent for p11 gene therapy in the treatment of psychiatric conditions, including depression, from Cornell University for and on behalf of the Joan & Sanford I. Weill Medical College. Neurologix scientific co-founder Michael G. Kaplitt, MD, PhD, is co-inventor on the patent, and is the senior author of the research paper.

"The publication of this important research validates our decision to secure the license for developing p11 gene therapy for eventual use in people with
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease

Post Your Comments:

(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... Institute, and Amgen (NASDAQ: AMGN ) ... collaboration to jointly discover and validate new therapeutic ... disease (IBD), a chronic disorder that affects millions ... expertise in clinical medicine, IBD biology, human genetics, ...

(Date:1/15/2014)... 2014 In an unprecedented effort to curb the spread ... ambulances and other transport vehicles, an advanced and portable UV ... rescue personnel for the first time. In ... in contact with these deadly pathogens, West Palm ... nation to begin sanitizing the interior surfaces of its ambulance ...

(Date:1/15/2014)... 2014 According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ... of these markets. The European radioembolization ...

Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2 Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3 Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4 Superbugs No Longer Ride In Rescue Vehicles 2 US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2 US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3

[0] Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease [0] Superbugs No Longer Ride In Rescue Vehicles [0] US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022

... , MARIETTA, Ga., Oct. 9 Solvay Pharmaceuticals, Inc. ... Journal of Cystic Fibrosis showed that CREON® ... therapy (PERT) in the United States, significantly improves a ... who suffer from exocrine pancreatic insufficiency (EPI). EPI is ...

... 8 American Scientific Resources Inc. (PINK SHEETS: ASFX) is ... ending December 31, 2007 and December 31, 2008. These reports ... . , American ... leading provider of innovative next-generation, health, medical, and safety products ...

Cached Medicine Technology:Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis 2 Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis 3 Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis 4 Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis 5 American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008 2

Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis American Scientific Resources Inc. Discloses Audited Financials for 2007 and 2008

(Date:3/10/2014)... Major League Baseball players who undergo Tommy John ... they had before surgery, according to a Henry Ford ... show a link between the surgery and declining pitching ... largest cohort of professional pitchers to date to examine ... MLB pitchers before and after surgery between 1982 and ...

(Date:3/10/2014)... ORLEANS─Ulnar collateral ligament (UCLR) reconstruction, otherwise known as "Tommy ... League Baseball (MLB) pitchers with a damaged or torn ... overuse. , In the new study, "Rate ... Surgery in Major League Baseball Pitchers," * presented today ... of Orthopaedic Surgeons (AAOS), researchers looked at the rate ...

(Date:3/10/2014)... senior athletes are high functioning despite having one ... onset osteoarthritis (OA): developmental dislocation of the ... impingement (FAI), a condition in which the hip ... presented today at the 2014 Annual Meeting of ... In the study, "Prevalence of Radiographic Abnormalities in ...

(Date:3/10/2014)... CAPE TOWN, ZA, March 11, 2014 Aeras today ... (TB) vaccine trial designed to study prevention of ... II study of the TB vaccine candidate, H4+IC31 (AERAS-404), ... infection by Mtb, the bacterium that causes TB. The ... also evaluate BCG revaccination. , This novel trial ...

(Date:3/10/2014)... Some sour news for lactose-intolerant people who hoped that ... milk: A pilot study from the Stanford University School ... two. , The study was small it involved ... results were highly consistent among all the participants and ... milk. , "It,s not that there was a trend ...

Breaking Medicine News(10 mins):Health News:Study: MLB pitchers don't regain performance level after Tommy John surgery 2 Health News:Study: MLB pitchers don't regain performance level after Tommy John surgery 3 Health News:Novel vaccine trial design aims to answer key TB questions 2 Health News:Novel vaccine trial design aims to answer key TB questions 3 Health News:Claim that raw milk reduces lactose intolerance doesn't pass smell test, study finds 2 Health News:Claim that raw milk reduces lactose intolerance doesn't pass smell test, study finds 3 Health News:Claim that raw milk reduces lactose intolerance doesn't pass smell test, study finds 4

[0] Study: MLB pitchers don't regain performance level after Tommy John surgery [0] Major League Baseball players win more games following Tommy John surgery [0] Genetics may explain high-functioning senior athletes with hip abnormalities [0] Novel vaccine trial design aims to answer key TB questions [0] Claim that raw milk reduces lactose intolerance doesn't pass smell test, study finds

... the,publication of its Q1 2007/2008 Earnings Results, Unilabs (SWX: ULB), ... on Tuesday, November 13th, 2007, at 16:00 p.m. CET, Central ... ask questions, please dial,one of the following numbers between 10 ... Switzerland, 16:00 pm (CET, Central European Time), ...

... compound that blocks the breakdown of retinoic acid, derived ... agent in treating animal models of human prostate cancer, ... , Daily injections of the agent VN/14-1 resulted ... volume in mice implanted with human prostate cancer cells, ...

... Highlights: ... - 100% contract renewal for 11 consecutive annual cycles ... initiative acquisition - Diluted earnings per share of ... Service,Corporation (Nasdaq: PRSC ) today announced financial results for the third,quarter ended ...

... third quarter 2006 -- Net loss narrows to $2.6 million - record performance,-- ... ... ... ...

... would affect both domestic and imported items, agency says ... recent U.S. outbreaks of illness linked to domestic and ... will ask Congress to give it the authority to ... FDA officials announced Tuesday. , Currently, the agency can ...

... Member of the National Institutes of Health Advisory ... Nov. 6 Today, AARP Illinois,announced the appointment ... this lead volunteer position, Haughton-Pitts will be a ... AARP,s state agenda., An advocate of health ...

Unilabs Q1 2007/2008 Earnings Conference Call Drug slows prostate tumor growth by keeping vitamin A active Providence Service Corporation Announces 35% Revenue Growth with Third Quarter Results; Increases Revenue Guidance for 2007 AtriCure Reports Third Quarter 2007 Financial Results FDA Seeks Food Recall Authority Haughton-Pitts Joins AARP Illinois Executive Council

... biocompatibility is established. Provides a robust and ... correct positioning on the globe. Pressure Ridge ... when covered by Tenons tissue, acts as ... hypotony. The range of implants allows the ...

... Long-term biocompatibility is established. Provides a ... holes ensure correct positioning on the globe. ... ridge which, when covered by Tenons tissue, ... limiting postoperative hypotony. The range of implants ...

... a low implant profile, 0.84mm, for better ... insertion is technically simpler and allows a ... installed with less trauma than multiple quadrant ... implant were designed to minimize bleb height ...

... Easyfield is lightweight enough to shuttle easily ... case. Designed with a goldmann standard 30 ... grid with 79 locations (including 30-2, 24-2, ... 3 different suprathresholds out to 30. ...

Medicine Products:

Pressure Ridge Double Plate Molteno Implant (DR2/DL2)Pressure Ridge Single Plate Molteno Implant (D1)Baerveldt Glaucoma Implant Easyfield